Wnt signaling in triple negative breast cancer is associated with metastasis

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Dey, Nandini ^a,b   Barwick, Benjamin G ^e   Moreno, Carlos S ^d,e   Ordanic Kodani, Maja ^j   Chen, Zhengjia ^f   Oprea Ilies, Gabriella ^d   Tang, Weining ^e   Catzavelos, Charles ^g,k   Kerstann, Kimberly F ^e   Sledge, George W ^h   Abramovitz, Mark ^i,l   Bouzyk, Mark ^c   De, Pradip ^a,b   Leyland Jones, Brian R ^a,b  

^a SANFORD RESEARCH   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c AKESOgen Inc ^*  (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

^f EMORY UNIVERSITY   (United States)

^g MCGILL UNIVERSITY   (Canada)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ VM Institute of Research   (Canada)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^k Ville Marie Multidisciplinary Medical Centre   (Canada)

^l UNIVERSITY OF MONTREAL   (Canada)

more..

Author keywords

Breast cancer; FFPE; Microarray; Triple negative; Wnt

Indexed keywords

BETA CATENIN; F ACTIN; FIBRONECTIN; GROWTH FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WNT PROTEIN; WNT3A PROTEIN; WNTC59 PROTEIN; MESSENGER RNA; PARAFFIN; TUMOR MARKER;

ARTICLE; BETA CATENIN GENE; BREAST TUMOR; CELL INVASION; DISEASE ASSOCIATION; GENE EXPRESSION; GENE TARGETING; GENETIC MANIPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; METASTASIS; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TRANSPORT; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; UPREGULATION; WNT GENE; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; BONE TUMOR; BRAIN TUMOR; CANCER STAGING; CELL MOTION; CELL PROLIFERATION; COHORT ANALYSIS; DNA MICROARRAY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR RECURRENCE; WESTERN BLOTTING;

BETA CATENIN; BIOMARKERS, TUMOR; BLOTTING, WESTERN; BONE NEOPLASMS; BRAIN NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAFFIN EMBEDDING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED; WNT PROTEINS;

EID: 84887089961     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-537     Document Type: Article

References (76)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
2. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D. How basal are triple-negative breast cancers?. Int J Cancer 2008, 123(1):236-240. 10.1002/ijc.23518, 18398844.
3. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69(10):4116-4124. 10.1158/0008-5472.CAN-08-3441, 2737191, 19435916.
4. Peddi PF, Ellis MJ, Ma C. Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012, 2012:217185. 3262606, 22295242.
5. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40(5):499-507. 10.1038/ng.127, 2912221, 18443585.
6. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009, 106(33):13820-13825. 10.1073/pnas.0905718106, 2720409, 19666588.
7. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486(7403):395-399. 3863681, 22495314.
8. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464(7291):999-1005. 10.1038/nature08989, 2872544, 20393555.
9. Carey LA. Directed therapy of subtypes of triple-negative breast cancer. Oncologist 2011, 16(Suppl 1):71-78.
10. Moulder SL. Does the PI3K pathway play a role in basal breast cancer?. Clin Breast Cancer 2010, 10(Suppl 3):S66-S71.
11. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009, 15(14):4649-4664. 10.1158/1078-0432.CCR-09-0317, 19567590.
12. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R, Reis-Filho JS. Beta-catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 2011, 24(2):209-231. 10.1038/modpathol.2010.205, 21076461.
13. Abramovitz M, Ordanic-Kodani M, Wang Y, Li Z, Catzavelos C, Bouzyk M, Sledge GW, Moreno CS, Leyland-Jones B. Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques 2008, 44(3):417-423. 10.2144/000112703, 2672087, 18361796.
14. Abramovitz M, Barwick BG, Willis S, Young B, Catzavelos C, Li Z, Kodani M, Tang W, Bouzyk M, Moreno CS, et al. Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform. Br J Cancer 2011, 105(10):1574-1581. 10.1038/bjc.2011.355, 3242517, 22067903.
15. Dey N, De PK, Wang M, Zhang H, Dobrota EA, Robertson KA, Durden DL. CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation. Mol Cell Biol 2007, 27(11):4179-4197. 10.1128/MCB.01352-06, 1900023, 17325034.
16. Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, Durden DL. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res 2008, 68(6):1862-1871. 10.1158/0008-5472.CAN-07-1182, 18339867.
17. Dey N, Young B, Abramovitz M, Bouzyk M, Barwick B, De P, Leyland-Jones B. Differential activation of Wnt-b-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner. PLoS One 2013, In Press.
18. Zeng G, Apte U, Cieply B, Singh S, Monga SP. siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 2007, 9(11):951-959. 10.1593/neo.07469, 2077886, 18030363.
19. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98(9):5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
20. Reimers M, Carey VJ. Bioconductor: an open source framework for bioinformatics and computational biology. Methods Enzymol 2006, 411:119-134.
21. Kanehisa M. The KEGG database. Novartis Found Symp 2002, 247:91-101. discussion 101-103, 119-128, 244-152.
22. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439(7074):353-357. 10.1038/nature04296, 16273092.
23. Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30(1):207-210. 10.1093/nar/30.1.207, 99122, 11752295.
24. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massague J. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009, 138(1):51-62. 10.1016/j.cell.2009.04.030, 2742946, 19576624.
25. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459(7249):1005-1009. 10.1038/nature08021, 2698953, 19421193.
26. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8(5):R76. 10.1186/gb-2007-8-5-r76, 1929138, 17493263.
27. Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007, 8:258. 10.1186/1471-2164-8-258, 2014778, 17663798.
28. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25(10):1239-1246. 10.1200/JCO.2006.07.1522, 17401012.
29. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436(7050):518-524. 10.1038/nature03799, 1283098, 16049480.
30. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27(8):1160-1167. 10.1200/JCO.2008.18.1370, 2667820, 19204204.
31. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005, 7(6):R953-R964. 10.1186/bcr1325, 1410752, 16280042.
32. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-679. 10.1016/S0140-6736(05)17947-1, 15721472.
33. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002, 99(10):6567-6572. 10.1073/pnas.082099299, 124443, 12011421.
34. Fan JB, Yeakley JM, Bibikova M, Chudin E, Wickham E, Chen J, Doucet D, Rigault P, Zhang B, Shen R, et al. A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 2004, 14(5):878-885. 10.1101/gr.2167504, 479115, 15123585.
35. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H, et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 2007, 104(16):6740-6745. 10.1073/pnas.0701138104, 1871856, 17420468.
36. Wang PS, Chou FS, Bloomston M, Vonau MS, Saji M, Espinosa A, Pinzone JJ. Thiazolidinediones downregulate Wnt/beta-catenin signaling via multiple mechanisms in breast cancer cells. J Surg Res 2009, 153(2):210-216. 10.1016/j.jss.2008.05.032, 18639247.
37. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006, 66(21):10292-10301. 10.1158/0008-5472.CAN-05-4414, 17079448.
38. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 2009, 106(31):12903-12908. 10.1073/pnas.0810402106, 2722321, 19617568.
39. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008, 68(9):3108-3114. 10.1158/0008-5472.CAN-07-5644, 18451135.
40. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 2010, 176(6):2911-2920. 10.2353/ajpath.2010.091125, 2877852, 20395444.
41. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009, 69(13):5364-5373. 10.1158/0008-5472.CAN-08-4135, 2782448, 19549913.
42. Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C, Keller ET, Li Y. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer 2008, 123(5):1034-1042. 10.1002/ijc.23625, 3732167, 18546262.
43. Vashisht S, Bagler G. An approach for the identification of targets specific to bone metastasis using cancer genes interactome and gene ontology analysis. PLoS One 2012, 7(11):e49401. 10.1371/journal.pone.0049401, 3498148, 23166660.
44. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005, 10(2):169-180. 10.1007/s10911-005-5399-8, 16025223.
45. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 2009, 13(4):485-496. 10.1517/14728220902841961, 3023986, 19335070.
46. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006, 116(5):1202-1209. 10.1172/JCI28551, 1451219, 16670761.
47. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. Journal of cell science 2006, 119(Pt 7):1283-1296.
48. Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z, Frenkel B. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res 2011, 13(6):R127. 10.1186/bcr3073, 3326569, 22151997.
49. Marchio C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, et al. The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 2008, 216(4):399-407. 10.1002/path.2423, 18810758.
50. Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004, 64(23):8541-8549. 10.1158/0008-5472.CAN-04-1992, 15574760.
51. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005, 205(2):248-254. 10.1002/path.1691, 15641021.
52. Melchor L, Honrado E, Huang J, Alvarez S, Naylor TL, Garcia MJ, Osorio A, Blesa D, Stratton MR, Weber BL, et al. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Clin Cancer Res 2007, 13(24):7305-7313. 10.1158/1078-0432.CCR-07-0711, 18094411.
53. Korsching E, Packeisen J, Helms MW, Kersting C, Voss R, van Diest PJ, Brandt B, van der Wall E, Boecker W, Burger H. Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. Br J Cancer 2004, 90(7):1422-1428. 10.1038/sj.bjc.6601658, 2409666, 15054466.
54. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer discovery 2013, 3(1):27-34. 10.1158/2159-8290.CD-12-0462, 3553590, 23319768.
55. Sircoulomb F, Bekhouche I, Finetti P, Adelaide J, Ben Hamida A, Bonansea J, Raynaud S, Innocenti C, Charafe-Jauffret E, Tarpin C, et al. Genome profiling of ERBB2-amplified breast cancers. BMC cancer 2010, 10:539. 10.1186/1471-2407-10-539, 2958950, 20932292.
56. Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther 2013, 12(1):104-116. 10.1158/1535-7163.MCT-12-0781, 23171949.
57. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998, 281(5382):1509-1512.
58. Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, Whitfield ML, Cole MD. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One 2009, 4(8):e6693. 10.1371/journal.pone.0006693, 2723908, 19690609.
59. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999, 155(4):1033-1038. 10.1016/S0002-9440(10)65204-2, 1867011, 10514384.
60. Masckauchan TN, Shawber CJ, Funahashi Y, Li CM, Kitajewski J. Wnt/beta-catenin signaling induces proliferation, survival and interleukin-8 in human endothelial cells. Angiogenesis 2005, 8(1):43-51. 10.1007/s10456-005-5612-9, 16132617.
61. Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ, Boman BM. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001, 61(24):8664-8667.
62. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2002, 2:8. 10.1186/1471-213X-2-8, 117803, 12095419.
63. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 1999, 154(2):515-523. 10.1016/S0002-9440(10)65297-2, 1850011, 10027409.
64. Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 2002, 62(18):5126-5128.
65. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99(3):335-345. 10.1016/S0092-8674(00)81664-5, 3779681, 10555149.
66. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ, et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999, 96(4):1603-1608. 10.1073/pnas.96.4.1603, 15532, 9990071.
67. ten Berge D, Koole W, Fuerer C, Fish M, Eroglu E, Nusse R. Wnt signaling mediates self-organization and axis formation in embryoid bodies. Cell Stem Cell 2008, 3(5):508-518. 10.1016/j.stem.2008.09.013, 2683270, 18983966.
68. Aarnisalo P, Palvimo JJ, Janne OA. CREB-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci USA 1998, 95(5):2122-2127. 10.1073/pnas.95.5.2122, 19270, 9482849.
69. Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Oncogene 2003, 22(36):5602-5613. 10.1038/sj.onc.1206802, 12944908.
70. Gerin I, Bommer GT, Lidell ME, Cederberg A, Enerback S, Macdougald OA. On the role of FOX transcription factors in adipocyte differentiation and insulin-stimulated glucose uptake. J Biol Chem 2009, 284(16):10755-10763. 10.1074/jbc.M809115200, 2667763, 19244248.
71. Kurahashi T, Nomura T, Kanei-Ishii C, Shinkai Y, Ishii S. The Wnt-NLK signaling pathway inhibits A-Myb activity by inhibiting the association with coactivator CBP and methylating histone H3. Mol Biol Cell 2005, 16(10):4705-4713. 10.1091/mbc.E05-05-0470, 1237076, 16055500.
72. Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011, 121(10):3786-3788. 10.1172/JCI60534, 3195489, 21965334.
73. Bertos NR, Park M. Breast cancer - one term, many entities?. J Clin Invest 2011, 121(10):3789-3796. 10.1172/JCI57100, 3195465, 21965335.
74. Han A, Song Z, Tong C, Hu D, Bi X, Augenlicht LH, Yang W. Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol 2008, 583(1):26-31. 10.1016/j.ejphar.2007.12.034, 2350231, 18291362.
75. Lee HJ, Wang NX, Shi DL, Zheng JJ. Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein dishevelled. Angew Chem Int Ed Engl 2009, 48(35):6448-6452. 10.1002/anie.200902981, 2978498, 19637179.
76. Lu W, Tinsley HN, Keeton A, Qu Z, Piazza GA, Li Y. Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol 2009, 602(1):8-14. 10.1016/j.ejphar.2008.10.053, 2637082, 19026633.